Variable expressivity familial cherubism: Woman transmitting cherubism without suffering the disease

Cherubism is classified within the group of benign osteo-fibrous lesions. Aside from facial deformities, it may account for major complications. It has been observed that the disease is caused by a mutation in the gene SH3BP2 (SH3-domain binding protein 2), which is located at chromosome 4pl6.3. Her...

Descripción completa

Detalles Bibliográficos
Autores: Pérez Sayáns, Mario, Barros Angueira, Francisco, Suárez Peñaranda, Jose Manuel, García García, Abel
Tipo de recurso: artículo
Fecha de publicación:2013
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/3693
Acceso en línea:http://hdl.handle.net/20.500.11940/3693
Access Level:acceso abierto
Palabra clave:Adaptor Proteins, Signal Transducing
Cherubism
Genes, Dominant
Mutation, Missense
Proteínas Adaptadoras Transductoras de Señales
Genes Dominantes
Mutación Missense
Querubismo
Descripción
Sumario:Cherubism is classified within the group of benign osteo-fibrous lesions. Aside from facial deformities, it may account for major complications. It has been observed that the disease is caused by a mutation in the gene SH3BP2 (SH3-domain binding protein 2), which is located at chromosome 4pl6.3. Here we present two cases of familial cherubism, uncle and nephew, with variable clinical involvement ("Expressivity"), and one case of a woman (sister and mother, respectively), who transmitted cherubism without suffering the disease. In this article we have shown that, in familial cherubism cases, the mutation is inherited through an autosomal dominant transmission. Mutations affecting gene SH3BP2 cause variable clinical involvement (variable expressivity), involvement can be moderate, severe or may result merely in asymptomatic carriers. Since the possibility of transmission reaches 50% of chances, we believe that it is important to develop genetic counseling for both patients and carriers, in order to prevent or minimize new affected offspring.